<DOC>
	<DOCNO>NCT00217711</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , oxaliplatin , irinotecan , capecitabine , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose capecitabine give together oxaliplatin irinotecan see well work treat patient advanced metastatic colorectal cancer remove surgery .</brief_summary>
	<brief_title>Oxaliplatin , Irinotecan , Capecitabine Treating Patients With Advanced Metastatic Colorectal Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose recommended phase II dose capecitabine administer combination oxaliplatin irinotecan patient unresectable advanced metastatic colorectal cancer . ( Phase I ) - Determine efficacy regimen patient . ( Phase II ) Secondary - Determine tolerability regimen patient . ( Phase II ) OUTLINE : This multicenter , phase I dose-escalation study capecitabine follow phase II study . - Phase I : Patients receive oxaliplatin IV 2 hour day 1 15 , irinotecan IV 1 hour day 8 22 , oral capecitabine twice daily day 1-29 . Treatment repeat every 5 week 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos capecitabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . - Phase II : Patients receive capecitabine MTD irinotecan oxaliplatin phase I . After completion study treatment , patient follow every 2 month 1 year every 4 month thereafter . PROJECTED ACCRUAL : A total 23-32 patient ( 3-12 phase I portion 20 phase II portion ) accrue study within 2.75 year</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm unresectable advanced metastatic colorectal cancer Measurable disease ( phase II ) At least 1 unidimensionally measurable lesion ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan MRI No presence history CNS metastases PATIENT CHARACTERISTICS : Age 18 70 Performance status WHO 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin ≤ 1.25 time upper limit normal ( ULN ) ( 1.5 time ULN liver metastasis present ) AST ALT ≤ 3 time ULN ( 5 time ULN liver metastasis present ) Renal Creatinine clearance &gt; 60 mL/min Cardiovascular No New York Heart Association class IIIIV congestive heart failure No symptomatic coronary artery disease No uncontrolled cardiac arrhythmia No myocardial infarction within past year No clinically significant cardiac disease Immunologic No active autoimmune disease No uncontrolled infection No prior severe reaction fluoropyrimidine therapy know hypersensitivity fluorouracil No known hypersensitivity component study drug Other Not pregnant nursing Negative pregnancy test Patients must use effective contraception 1 year study participation No malignancy within past 5 year except adequately treat carcinoma situ cervix localize nonmelanoma skin cancer No peripheral neuropathy &gt; grade 1 origin ( e.g. , alcohol diabetes ) No nausea , vomit , malabsorption syndrome would preclude ingestion absorption oral medication No psychiatric disability would preclude study compliance No uncontrolled diabetes No serious underlie medical condition would preclude study participation No known dihydropyrimidine dehydrogenase deficiency PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent prophylactic hematopoietic growth factor Chemotherapy More 6 month since prior adjuvant fluoropyrimidine chemotherapy No prior chemotherapy Endocrine therapy Not specify Radiotherapy No concurrent radiotherapy Concurrent radiotherapy single painful lesion allow Surgery Not specify Other More 30 day since prior clinical trial participation No concurrent experimental drug No concurrent anticancer therapy No concurrent sorivudine chemicallyrelated analogue ( e.g. , lamivudine )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>